The Latest

With the Public Attuned to Drug Pricing, Advocates Request Affordable Rate for New HIV Drug

The Fair Pricing Coalition says that patients, insurers and public programs shouldn't have to pay higher costs for a next-generation HIV treatment could make combination therapy less toxic.

By Jennifer Johnson Avril

Gilead Sciences First-Quarter Profits Driven by Increase in Sales of Antiretroviral Viread

Foster City, Calif.-based Gilead Sciences on Thursday announced first-quarter 2004 net profits of $114.4 million, up from a net loss of $438.1 million during the same quarter last year, an increase largely driven by sales of its antiretroviral drug V...

By Henry J. Kaiser Family Foundation

Atazanavir (Reyataz): New Recommendations if Combined With Tenofovir (Viread) -- and Warning on Viagra, Cialis, and Levitra

On March 19, 2004 the FDA notified the public of new prescribing information and precautions for atazanavir (brand name Reyataz), if taken in combination with tenofovir (Viread) -- and warned of risks with Viagra or similar drugs.

If atazanavir is t...

By AIDS Treatment News

U.S. Approves Emtriva; Gilead Hopes Viread/Emtriva Combo Will Compete With Combivir

Gilead Sciences received approval from the US Food and Drug Administration Wednesday for a new once-a-day AIDS drug, Emtriva. Known generically as emtricitabine, Emtriva is a nucleoside reverse transcriptase inhibitor. Gilead now hopes to combine Emt...

By CDC National Prevention Information Network

Tenofovir DF on the Horizon

A new drug application for Tenofovir disoproxil fumarate (Tenofovir DF) has been filed with the Food and Drug Administration by Gilead Sciences. Tenofovir DF, also known as PMPA, could be approved within the next six months.

Tenofovir DF is an inves...

By Liliana Eagan for AIDS Project Los Angeles

Tenofovir: FDA Hearing October 3, Public Comment Deadlines September 26

On October 3 the FDA's Antiviral Drugs Advisory Committee will hold a public hearing on tenofovir (full chemical name tenofovir disoproxil fumarate, or tenofovir DF; new brand name Viread™, an antiretroviral developed by Gilead Sciences and currently...

By John S. James for AIDS Treatment News

Tenofovir: Gilead Applies for Approval; Expanded Access Liberalized

Tenofovir, Gilead Sciences' candidate reverse transcriptase inhibitor, could be approved in about six months. In an unexpected move, the company announced May 1 that it had filed a New Drug Application with the FDA. After approval, tenofovir could be...

By Dave Gilden for AIDS Treatment News

Tenofovir Compassionate Use Program

Gilead has announced a small compassionate access study of tenofovir, a prodrug of PMPA. As with ABT-378, there is limited availability of the drug, so entry criteria are fairly restrictive. Patients must be between 18 and 65, have HIV RNA of at leas...

By Gay Men's Health Crisis

PMPA: Experimental Drug That Completely Protects Monkeys Exposed to SIV

This is a statement from the National Institutes of Health (NIH) concerning an experimental drug that completely protects monkeys exposed to SIV.

An experimental drug called PMPA given to 25 macaque monkeys up to a day after they were exposed to sim...

By Centers for Disease Control and Prevention